SPH4336 vs Tibremciclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
SPH4336
Developed by Shanghai Pharmaceuticals Holding
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05860465 (registry estimate)
No aligned efficacy figure on record for this race.
Tibremciclib · Kangmeina
Marketed by Betta Pharmaceuticals Co.
NCT05433480 · Phase 3 · status unknown
This randomised, quadruple-blind, placebo-controlled trial in 274 women with HR-positive, HER2-negative advanced breast cancer reported median progression-free survival of 16.5 months with tibremciclib plus fulvestrant against 5.6 months with placebo plus fulvestrant, a hard clinical endpoint.
Result from the peer-reviewed publication (JAMA Oncology 2025); the registry has no posted results and its status is not updated.
Reported efficacy
Investigator-assessed PFS (up to 3 years): Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001 (met)
Result source: NCT05433480
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | SPH4336 | Tibremciclib |
|---|---|---|
| PFS, median | —Trial running · NCT05744687 | —Not reported |
| OS, median | —Trial running · NCT05744687 | —Not reported |
| ORR | —Trial running · NCT05744687 | —Not reported |
| Clinical benefit rate | —Trial running · NCT05744687 | —Not reported |
PFS, median
- SPH4336
- —Trial running · NCT05744687
- Tibremciclib
- —Not reported
OS, median
- SPH4336
- —Trial running · NCT05744687
- Tibremciclib
- —Not reported
ORR
- SPH4336
- —Trial running · NCT05744687
- Tibremciclib
- —Not reported
Clinical benefit rate
- SPH4336
- —Trial running · NCT05744687
- Tibremciclib
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SPH4336: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SPH4336's landscape · Tibremciclib's landscape